Navigation Links
AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
Date:7/17/2009

RESEARCH TRIANGLE PARK, N.C., July 17 /PRNewswire/ -- AlphaVax, Inc. announced today that it has completed process development and preclinical immunogenicity studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. This vaccine has shown good production yields as well as excellent immunogenicity, even after just a single inoculation.

"Our vaccine platform provides several potential advantages over other influenza vaccine approaches in that vaccines can be rapidly constructed and tested, and are produced in cell culture systems rather than eggs. In addition, our vaccines do not require the use of an adjuvant, and they raise not only strong antibody responses but robust cellular responses, both of which could be important in the face of a developing pandemic where there are several variant virus forms circulating," said Jonathan Smith, AlphaVax's Chief Scientific Officer.

The studies performed at AlphaVax utilized the California 04/2009 HA sequence obtained from the WHO GISAID database on April 25th. Mice inoculated with the AlphaVax H1N1 vaccine showed strong dose-dependent hemagglutination inhibition ("HI") antibody responses. After just a single dose of the H1N1 vaccine, all vaccinated animals developed HI antibody levels considered to be protective. These responses were boosted approximately 8-fold by a second dose given three weeks later. Responses measured by ELISA and ELISPOT assays, which assess antibody and T cell responses, respectively, mirrored the HI responses. The design of future clinical trials of this vaccine will be based on two previous successful influenza vaccine trials run by AlphaVax, one carried out in healthy young adults and the other in an elderly population.

According to Andrew Graham, AlphaVax's Vice President for Development and Technical Operations, "AlphaVax will begin GMP-compliant manufacturing of this vaccine for clinical testing next week, which is less than three full months from our initial receipt of the gene sequence from the WHO. We are currently scaling up the process used to manufacture VRP vaccines and anticipate yields up to 1 million doses of pandemic influenza vaccine per lot at the 1,000 L bioreactor scale. Since the process is performed predominantly in disposable equipment, the design, construction and validation of a facility leading to the production of product for the market would be 1-2 years less than for a typical vaccine manufacturing facility."

About AlphaVax

AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the same manufacturing, formulation, and delivery strategies to be applied to many different products. The company's business strategy is to maximize the potential of this platform through a mixture of in-house and partnered programs. The AlphaVax technology is currently being used to advance vaccines for cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, influenza, HIV and a number of biodefense targets. The AlphaVax headquarters and R&D facilities are located in Research Triangle Park, and its GMP-compliant manufacturing facility is located in Lenoir, NC.


'/>"/>
SOURCE AlphaVax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. AlphaVax Announces Promising Results in Melanoma Studies
2. AlphaVax Continues to Expand the Use of Its Vaccine Platform
3. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
4. AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial
5. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
6. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
7. Elbit Imaging Ltd. Announces - Swiss Team Uses InSightecs ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders
8. Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris
9. Relievant Medsystems Announces Completion of $20 Million Financing
10. Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
11. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery ... 8.8% during the forecast period of 2016 to 2021. ... by 2021 from USD 18.21 billion in 2016. The ... rising incidences of sports related injuries and spinal problems, ... rising need of effective blood loss management. ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... largest share of the market in 2016 and is ... can be attributed to a large number of surgical ... hold the largest share in the patient temperature management ... such as reducing loss of blood during surgeries, lowering ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... ... "I have gout, and I wanted to treat it naturally," said an ... relieve gout and pain caused by varicose veins. I drank it every morning for ... what VA doctors called the worst sinusitis case they'd seen and relieved gas, stress ...
(Date:12/9/2016)... ... 2016 , ... Mediaplanet today announces distribution of the latest edition of “Transplants,” ... up as an organ donor for the 123,000 people in the United States who ... save up to 8 saves through organ donation and enhance many others through tissue ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... through the Pennsylvania Cable Network (PCN) during the summer of 2016. The program ... Grant provided by the United States Department of Health and Human Services Administration. ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...
Breaking Medicine News(10 mins):